UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. )*

MTS Medication Technologies, Inc.

(Name of Issuer)

Common Stock, $.01 par value per share

(Title of Class of Securities)

553773102

(CUSIP Number)

December 1, 2009

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     o Rule 13d-1(b)

     þ Rule 13d-1(c)

     o Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 553773102 

1	NAMES OF REPORTING PERSONS Bradley Louis Radoff
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States of America
		5	SOLE VOTING POWER
NUMBER OF			495,500
SHARES		6	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			0
EACH		7	SOLE DISPOSITIVE POWER
REPORTING
PERSON			495,500
WITH:		8	SHARED DISPOSITIVE POWER
			0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	495,500
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	7.6%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN

2

SCHEDULE 13G

          This Schedule 13G (this “Schedule 13G”) is being filed on behalf of Bradley Louis Radoff relating to the Common Stock, $.01 par value per share (the “Common Stock”), of MTS Medication Technologies, Inc., a Delaware corporation (the “Issuer”), purchased by Mr. Radoff.

Item 1(a)	Name of Issuer.
	MTS Medication Technologies, Inc.
Item 1(b)	Address of Issuer’s Principal Executive Offices.
	2003 Gandy Boulevard North
	St. Petersburg, Florida 33702
Item 2(a)	Name of Person Filing.
	Mr. Bradley Louis Radoff
Item 2(b)	Address of Principal Business Office, or, if non, Residence
	1177 West Loop South
	Suite 1625
	Houston, Texas 77027
Item 2(c)	Place of Organization.
	Mr. Radoff is a U.S. citizen.
Item 2(d)	Title of Class of Securities.
	Common Stock, $.01 par value per share (the “Common Stock”)
Item 2(e)	CUSIP Number.
	553773102
Item 3	Reporting Person.
	The person filing is not listed in Items 3(a) through 3(j).
Item 4	Ownership.

(a)	Mr. Radoff is the beneficial owner of 495,500 shares of Common Stock.
(b)	Mr. Radoff beneficially owns 495,500 shares of Common Stock, which represents approximately 7.6% of the shares of Common Stock outstanding.

3

	This percentage is determined by dividing the number of shares beneficially held by Mr. Radoff by 6,481,315, the number of shares of Common Stock outstanding as of November 13, 2009, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 16, 2009.
(c)	Mr. Radoff may direct the vote and disposition of 495,500 shares of Common Stock.

Item 5	Ownership of Five Percent or Less of a Class.
	Inapplicable.
Item 6	Ownership of More Than Five Percent on Behalf of Another Person.
	Inapplicable.
Item 7	Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.
	Inapplicable.
Item 8	Identification and Classification of Members of the Group.
	Inapplicable.
Item 9	Notice of Dissolution of Group.
	Inapplicable.
Item 10	Certification.
	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

4

SIGNATURE

          After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 11, 2009

/s/ Bradley Louis Radoff  

Bradley Louis Radoff 

5